Latest Transformation News

Elixinol Wellness has raised $2.5 million through a well-supported placement and appointed industry veteran Gavin Evans as strategic advisor to drive its next phase of growth and operational reset.

FirstWave Cloud Technology has completed a $1.6 million annual restructure aimed at driving growth through AI-powered compliance management and monetising its large free user base.

Asra Minerals has raised $3.25 million to fast-track exploration at its Leonora Gold Projects in Western Australia, targeting high-grade zones and new prospects.

Austral Resources Australia Ltd is advancing its strategy to become a mid-tier copper producer by consolidating key assets in Queensland’s Mount Isa copper belt, supported by a $40 million capital raise.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

MIXI Australia confirms its final $1.25 per share offer for PointsBet, now holding a majority stake and closing the bid on 12 September 2025. Shareholders face a decisive moment as the offer will not be extended or increased.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.

Hazer Group and First Graphene have signed a non-binding MOU to explore innovative applications for Hazer’s proprietary graphite, aiming to capitalize on rising global demand amid supply constraints.

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.

Delorean Corporation has locked in a long-term biomethane supply agreement with Origin Energy, underpinning its SA1 Salisbury bioenergy project with up to $40 million in revenue over 10 years.